The Latest

  • Employees working in the labs of Rapport Therapeutics, which recently began late-stage testing of a potentially first-of-its-kind seizure medication.
    Image attribution tooltip
    Permission granted by Rapport Therapeutics
    Image attribution tooltip
    Q&A

    Rapport ‘fully prepared’ to launch seizure drug solo, CEO says

    In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.

  • Winter snow covered mountain
    Image attribution tooltip

    Getty / Roberto Moiola

    Image attribution tooltip
    Sponsored by First Tracks Biotherapeutics

    Celiac disease is entering a new era of therapeutic innovation

    For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

  • 3D render using close-up of heart model covered with white, red, yellow pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Edgewise heart drug passes key trial test

    Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.

  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J multiple myeloma drug gains edge in earlier stage disease

    The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Neumora depression drug fails; EnGene to cut 50% of staff

    Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

  • Tennessee remittances tax government revenue payments
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Express Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

    Express Scripts and the PBM lobby are following in CVS Caremark’s footsteps in filing complaints challenging the FAIR Rx Act, which was passed earlier this year despite vehement opposition from PBMs.

  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare drug price rule may target under-the-skin Keytruda and Opdivo

    For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

  • china flag pill
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Amid a flurry of biotech deals, China looks to keep innovation at home

    The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.

  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly scores early positive data for new JAK drug

    Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Parabilis sets a record with a $670M biotech IPO

    The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined. 

  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis RNA drug acquired in $12B Avidity deal notches a trial win

    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Kardigan set terms Thursday for its IPO, which could bring in more than $373 million for the cardiac drugmaker as it seeks to be the 13th biotechnology company to go public in 2026.

    Updated June 11, 2026
  • Weight loss GLP-1
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

    At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit pulls $500M share sale a day after announcing it

    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    GSK’s $10.6 billion acquisition of Nuvalent is its third company buyout since late January and the biopharmaceutical sector’s second-largest deal this year.

    Updated June 9, 2026
  • An infant's left ear is in the foreground of this image, which is otherwise blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    Sanofi stops immune drug trial in latest research setback

    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.

  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ethyreal starts up with $101M and takes aim at a pair of immune diseases

    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AstraZeneca, Pfizer and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025 — surpassing all of their pharmaceutical peers over that timeframe.

    Updated June 1, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK boosts cancer pipeline with $11B Nuvalent buyout

    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

  • A person stands next to a table where another person sits.
    Image attribution tooltip
    Courtesy of Treeline Biosciences
    Image attribution tooltip
    Emerging biotech

    Stealthy startup Treeline plans a reverse merger

    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.

    Updated May 28, 2026
  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip
    Emerging biotech

    J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B

    The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.